ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3600
-0.0045 (-1.23%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.3645
Open0.3550
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3500 - 0.3750
52 Week Range0.2600 - 0.6900
Volume369,748
Avg. Volume220,033
Market Cap58.026M
Beta (3Y Monthly)-1.79
PE Ratio (TTM)N/A
EPS (TTM)-0.0540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

    FRAMINGHAM, Mass., March 11, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care.

  • GlobeNewswire2 months ago

    Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference

    FRAMINGHAM, Mass., Feb. 05, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire4 months ago

    Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019

    FRAMINGHAM, Mass., Dec. 20, 2018 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire4 months ago

    Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the 510(k) premarket notification for AC5™ Topical Gel has been reviewed and cleared by the U.S. Food and Drug Administration (FDA), allowing for the product to be marketed. AC5 Topical Gel is a topical dressing indicated for use in the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. Marketing clearance, which requires the provision of necessary documentation and data to the FDA, is an essential milestone to the path to commercialization.

  • GlobeNewswire5 months ago

    Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, presented an update on its corporate milestones, plans and timetables at the LD Micro Main Event XI in Los Angeles, California. Chief Executive Officer, Terrence W. Norchi, MD provided the following summary.

  • GlobeNewswire5 months ago

    Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

    FRAMINGHAM, Mass., Dec. 04, 2018 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire5 months ago

    Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe

    Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has submitted the required documents for AC5™ Topical Hemostat (AC5)1 to its Notified Body as it seeks a CE mark, which is a next step on the path to commercialization in countries governed by the European Medical Devices Directive (MDD). This first such submission by Arch to a European regulatory body follows the recent submission of a 510(k) premarket notification to the US Food and Drug Administration. Receipt of a CE mark would allow AC5 to be commercialized for use on external wounds, and in particular, for controlling bleeding by mechanically sealing areas of leakage and managing wounds in skin.

  • GlobeNewswire5 months ago

    Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the LD Micro Main Event XI. Chief Executive Officer, Terrence W. Norchi, MD will deliver a corporate presentation on Tuesday, December 4 at 12:00 PM Pacific Time in Track 1.